- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Rezolute, Inc. initiated clinical trials in Europe and received a streamlined development path from the FDA.
1 report, 1 independent
Updated Sep 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Rezolute, Inc. initiated clinical trials in Europe and received a streamlined development path from the FDA.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- Both the FDA and the European Medicines Agency govern drug approval processes.
- FDA approval enables commercial opportunity involving CBRE Group.
- Trinity Biotech announced that its Premier Hb9210™ analyser received FDA clearance and the company plans to accelerate growth across its diagnostics franchise in Europe.
- The FDA issued a Complete Response Letter regarding the RP1 BLA to Replimune Group, Inc. on August 7, 2025.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
Coverage
Newest first; wire copies grouped- GlobeNewswireRezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism Open-label study in as few as 16 tumor hyperinsulinism (HI) patients Study